Instylla

Executive Summary

Instylla is a privately held medical device company specializing in novel resorbable liquid embolic agents for minimally invasive interventional procedures. The company's flagship product, the Embrace™ Hydrogel Embolic System, has received FDA approval for the treatment of hypervascular tumors, offering deep and targeted embolization that resorbs over time to preserve future treatment options. With a strong foothold in interventional oncology, Instylla aims to address unmet needs in tumor embolization by providing a biocompatible, temporary embolic that maintains vessel patency for subsequent therapies. The technology platform is versatile and could potentially expand into other vascular interventions beyond oncology. As a private company with an approved product, Instylla is positioned for growth through commercialization and strategic partnerships. The company's focus on resorbable embolics differentiates it from permanent alternatives, potentially improving patient outcomes and expanding the addressable market. With a robust pipeline and a clear value proposition, Instylla represents a compelling opportunity in the interventional oncology space.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch and initial revenue ramp of Embrace system80% success
• TBDFDA approval for additional tumor indications or expanded label60% success
• Q4 2026Strategic partnership or licensing deal for global distribution50% success